Dr. Larson Ode from our division has co-authored two newly-published, peer‑reviewed articles in the journal titled Endocrine Practice.
Th first article examines the real-world practice of endocrinologists to manage dysglycemia in people with cystic fibrosis who do not meet criteria for cystic fibrosis–related diabetes (CFRD). The study, titled “Between the Guidelines: Variability in Management of Patients with Cystic Fibrosis & Dysglycemia,” reports findings from a national survey of U.S. endocrinologists with CF expertise. The challenge in management is that current guidelines do not address how to manage people with cystic fibrosis who have elevated blood sugar levels that are not high enough to meet criteria to be diagnosed as diabetes. The survey found substantial variation in clinical practice. One frequent approach was use of continuous glucose monitors, though access barriers and disagreement over which metrics are most meaningful highlight uncertainties. Use of lifestyle interventions and medications—including insulin and selected non‑insulin therapies—also varied widely. The results underscore the need for more standardized approaches to support future research and guide evidence‑based care. You can find the PubMed link to the full article here.
A second article reviews endocrine care for people with cystic fibrosis. The publication reviews the evolving endocrine and metabolic considerations in cystic fibrosis in the era of CFTR modulator therapies, with attention to diabetes, bone health, growth, and emerging metabolic risks. The article, “The Changing Landscape of Pediatric Endocrinology in Cystic Fibrosis: Insights from the Post‑CFTR Modulator Era,” emphasizes how advances in targeted CF therapies are reshaping long‑term endocrine management and highlights areas where ongoing research will be essential to guide best practices. You can find the PubMed link to the full article here.
